| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
GSK189254A (also known as GSK189254) is a novel histamine H(3) receptor antagonist with high affinity for human (pK(i) = 9.59 -9.90) and rat (pK(i) = 8.51-9.17) H(3) receptors. It has the potential for the treatment of narcolepsy. GSK189254 demonstrated strong functional antagonism (pA(2) = 9.06 versus agonist-induced changes in cAMP) and inverse agonism (pIC(50) = 8.20 versus basal guanosine 5'-O-(3-[(35)S]thio)triphosphate binding) at the human recombinant H(3) receptor, demonstrating its >10,000-fold selectivity for human H(3) receptors over other targets tested. Specific binding of [(3)H]GSK189254 was shown by in vitro autoradiography in the cortex and hippocampus of rats and humans. For the symptomatic treatment of dementia in Alzheimer's disease and other cognitive disorders, GSK189254 may have therapeutic potential.
| Targets |
H3, human ( pKi = 9.59-9.90 ); H3, rat ( pIC50 = 8.51-9.17 )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Animal Protocol |
Rats: GSK189254 pharmacokinetic studies are carried out in male Sprague-Dawley rats that are conscious. GSK189254 (n=3) is infused intravenously into the animals over the course of one hour at a nominal dose level of 1 mg of free base/kg through the use of a femoral vein cannula (10 mL/h/kg). To achieve the target concentration of 0.1 mg free base/mL, GSK189254 is dissolved in 0.9% (w/v) saline and filtered through a 0.22-mm Millex-GV filter prior to administration. The same rats were given a single oral dose of GSK189254 by gastric gavage after a period of at least two days, with the aim of achieving a dose of 2 mg of free base/kg. GSK189254 is designed to have a target concentration of 0.4 mg free base/mL in 1% (w/v) aqueous methylcellulose[1].
Mice: The vehicle is made up of 0.05 mL of 0.9% NaCl and 1% methylcellulose. It dissolves GSK189254 in the vehicle solution. GSK189254 is administered acutely and repeatedly to wild-type (Ox+/+) and orexin-knockout (Ox−/−) mice to examine its effects on the sleep-wake cycle. In Ox+/+ and Ox−/− mice, GSK189254 (3 and 10 mg/kg, p.o.) is dosed at 10 h during the sleep-wake cycle. GSK189254 is administered orally at a dose of 10 mg/kg[2].
|
|
| References |
| Molecular Formula |
C21H25N3O2
|
|
|---|---|---|
| Molecular Weight |
351.44
|
|
| Exact Mass |
351.19
|
|
| Elemental Analysis |
C, 71.77; H, 7.17; N, 11.96; O, 9.10
|
|
| CAS # |
720690-73-3
|
|
| Related CAS # |
945493-87-8 (HCl); 720690-73-3
|
|
| Appearance |
Powder
|
|
| SMILES |
CNC(=O)C1=CN=C(C=C1)OC2=CC3=C(CCN(CC3)C4CCC4)C=C2
|
|
| InChi Key |
WROHEWWOCPRMIA-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C21H25N3O2/c1-22-21(25)17-6-8-20(23-14-17)26-19-7-5-15-9-11-24(18-3-2-4-18)12-10-16(15)13-19/h5-8,13-14,18H,2-4,9-12H2,1H3,(H,22,25)
|
|
| Chemical Name |
6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8454 mL | 14.2272 mL | 28.4544 mL | |
| 5 mM | 0.5691 mL | 2.8454 mL | 5.6909 mL | |
| 10 mM | 0.2845 mL | 1.4227 mL | 2.8454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effects of acute and repeat administration of GSK189254 on mean duration (±SEM) of sleep–wake stages in a 4 h recording within the lights-on period in (A) wild-type (Ox+/+) and (B) Ox−/− mice (n= 14 per group). GSK189254 (3 and 10 mg·kg−1) significantly increased wakefulness (W) and decreased slow wave sleep (SWS) and paradoxical sleep (PS) following acute dosing.Br J Pharmacol.2009 May;157(1):104-17. |
|---|
Effects of acute and repeat administration of GSK189254 on mean duration (±SEM) of sleep–wake stages in a 4 h recording within the lights-off period in (A) wild-type (Ox+/+) and (B) Ox−/− mice (n= 14 per group). GSK189254 (3 and 10 mg·kg−1) significantly increased wakefulness (W) and decreased slow wave sleep (SWS) and paradoxical sleep (PS) following acute dosing.Br J Pharmacol.2009 May;157(1):104-17. |
H3(left panels) and H1(right panels) receptor binding in Ox+/+ and Ox−/− mice measured using [3H]-GSK189254 and [3H]-mepyramine respectively, with real-time autoradiography.
Effects of acute and repeat administration of GSK189254 and effect of acute administration of modafinil on narcoleptic attacks in Ox−/− mice in the lights-off period compared with vehicle-treated mice.Br J Pharmacol.2009 May;157(1):104-17. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
